Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
08 Novembre 2023 - 2:00PM
Business Wire
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical
company focused on discovering and developing potential
best-in-class medicines for serious and rare diseases, today
announced that senior management will participate in a fireside
chat at the Jefferies London Healthcare Conference on Wednesday,
November 15, 2023 at 4:00 p.m. GMT in London, UK.
A live webcast of the presentation can be accessed under “Events
and Presentations” on the Investors section of the Viridian website
at viridiantherapeutics.com. A replay of the webcast will be
available following the completion of the event.
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering
and developing potential best-in-class medicines for patients with
serious and rare diseases. Viridian’s expertise in antibody
discovery and engineering enables it to develop differentiated
therapeutic candidates for previously validated drug targets in
commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The company
is conducting two global Phase 3 studies (THRIVE and THRIVE-2) to
evaluate the safety and efficacy of VRDN-001 in patients with
active and chronic TED. Simultaneously, the company is developing
its subcutaneous program strategy with the goal of providing a
potentially more conveniently administered therapy to patients with
TED. In addition to its TED portfolio, Viridian is advancing a
novel portfolio of neonatal Fc receptor (FcRn) inhibitors with the
potential to be developed in multiple autoimmune diseases. Viridian
is also developing additional preclinical assets in autoimmune and
rare diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit www.viridiantherapeutics.com. Follow
Viridian on LinkedIn and X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108658074/en/
Louisa Stone, 617-272-4604 Manager, Investor Relations
IR@viridiantherapeutics.com
Matt Fearer, 617-272-4605 Vice President, Corporate
Communications Media@viridiantherapeutics.com
Grafico Azioni Viridian Therapeutics (NASDAQ:VRDN)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Viridian Therapeutics (NASDAQ:VRDN)
Storico
Da Set 2023 a Set 2024